Log in or Sign up for Free to view tailored content for your specialty!
Bone/Mineral Metabolism News
No link between calcium supplements, abdominal aortic calcification among older women

Older women randomly assigned a daily 1.2 g calcium supplement for 5 years were no more likely to develop abdominal aortic calcification vs. similar women assigned placebo, according to study data presented at the American Society for Bone and Mineral Research annual meeting.
Real-world study suggests high adherence for injectable osteoporosis therapy

A cohort of postmenopausal women with osteoporosis at high risk for fracture prescribed abaloparatide outside of a clinical trial setting reported high treatment satisfaction, with 94% of participants adhering to daily injections as prescribed, according to study data presented at the American Society for Bone and Mineral Research annual meeting.
Log in or Sign up for Free to view tailored content for your specialty!
Cost for osteoporosis care rose 118% over 15 years in US

Approximately 11% of middle-aged adults in the United States have osteoporosis, with the cost for care rising by nearly $50 billion over more than a decade, according to study data presented at the American Society for Bone and Mineral Research annual meeting.
Vitamin D deficiency tied to risk for diabetes death

Adults with vitamin D deficiency are more likely to die of complications from diabetes during 10 years of follow-up when compared with vitamin D-sufficient adults, according to study data presented at the European Association for the Study of Diabetes annual meeting.
Type 2 diabetes less likely with increasing plasma strontium levels

Adults with higher levels of plasma strontium were less likely to have type 2 diabetes or impaired glucose regulation than those with smaller amounts, according to findings published in Clinical Nutrition.
High-dose vitamin D supplementation may harm bone health

Healthy, middle-aged adults without osteoporosis assigned to a high-dose daily vitamin D liquid drop had reduced bone mineral density at 3 years when compared with similar adults assigned to a daily low-dose supplement, according to findings published in JAMA.
Long-term HT use not associated with fracture risk among transgender women

A Dutch cohort of older transgender women prescribed long-term gender-affirming hormone therapy had a 3-year fracture risk that was comparable to that of cisgender women, according to findings published in the Journal of Bone and Mineral Research.
Low-trauma fractures increase 1-year mortality risk in adults with neurodevelopmental delays

Compared with typical adults, those with neurodevelopmental disabilities may be more susceptible to early mortality following a low-trauma fracture, according to findings published in Bone.
Follicle-stimulating hormone may predict bone loss in premenopausal women

A one-time measurement of follicle-stimulating hormone during pre- or perimenopause may serve as an independent predictor of imminent bone loss, particularly at the lumbar spine, during the menopause transition, according to findings published in the Journal of Bone and Mineral Research.
BMD loss fails to recover after weight regain among older adults

In a cohort of older adults who lost weight while participating in a lifestyle program, both those who went on to maintain their weight loss and those who regained weight after the program were susceptible to reductions of bone mineral density at the hip, according to findings published in Obesity.
-
Headline News
Senate committee advances NIH, FDA leaders' nominations
March 13, 20252 min read -
Headline News
‘We are going to have difficulty’: Untangling causes of fatigue, long COVID remains elusive
March 14, 20255 min read -
Headline News
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
March 14, 20253 min read
-
Headline News
Senate committee advances NIH, FDA leaders' nominations
March 13, 20252 min read -
Headline News
‘We are going to have difficulty’: Untangling causes of fatigue, long COVID remains elusive
March 14, 20255 min read -
Headline News
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
March 14, 20253 min read